Literature DB >> 29796717

The Sleep Disorder in Anti-lgLON5 Disease.

Carles Gaig1,2,3,4, Alex Iranzo1,2,3,4, Joan Santamaria1,2,3,4, Francesc Graus5,6.   

Abstract

PURPOSE OF REVIEW: To review the clinical and polysomnographic features of the sleep disorder occurring in the recently described anti-IgLON5 disease. The hallmark of the disease is the presence of antibodies against IgLON5, a neural cell adhesion molecule of unknown function. The disease presents a robust HLA association, and the neuropathological examination shows a novel neuronal tauopathy with predominant hypothalamic and brainstem involvement. RECENT
FINDINGS: Most patients (> 80%) present sleep-related vocalizations with movements and behaviors and sleep-disordered breathing. Polysomnographic studies show (1) a complex NREM sleep parasomnia at sleep initiation characterized by undifferentiated NREM or poorly structured N2 sleep with sleep-talking or mumbling, and simple or finalistic movements followed by normal periods of N3 or N2 NREM sleep, (2) REM sleep behavior disorder (RBD), and (3) obstructive sleep apnea with stridor. The last two features appear mainly in periods where NREM sleep normalizes. Identification of the anti-IgLON5 sleep disorder is important to suspect the disease. The combination of abnormal NREM sleep initiation, followed by normal periods of NREM sleep and RBD, represents a novel parasomnia.

Entities:  

Keywords:  Anti-IgLON5 disease; NREM onset parasomnia; REM sleep behavior disorder; Sleep-breathing disorder; Stridor; Tauopathy

Mesh:

Year:  2018        PMID: 29796717     DOI: 10.1007/s11910-018-0848-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  23 in total

Review 1.  Agrypnia Excitata: a generalized overactivity syndrome and a useful concept in the neurophysiopathology of sleep.

Authors:  P Montagna; E Lugaresi
Journal:  Clin Neurophysiol       Date:  2002-04       Impact factor: 3.708

2.  The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG).

Authors:  Marco Zucconi; Raffaele Ferri; Richard Allen; Paul Christian Baier; Oliviero Bruni; Sudhansu Chokroverty; Luigi Ferini-Strambi; Stephany Fulda; Diego Garcia-Borreguero; Wayne A Hening; Max Hirshkowitz; Birgit Högl; Magdolna Hornyak; Martin King; Pasquale Montagna; Liborio Parrino; Giuseppe Plazzi; Mario G Terzano
Journal:  Sleep Med       Date:  2006-02-03       Impact factor: 3.492

3.  Immunotherapy of oneiric stupor in Morvan syndrome: Efficacy documented by actigraphy.

Authors:  Simone Baiardi; Federica Provini; Patrizia Avoni; Marco Pasquinelli; Rocco Liguori
Journal:  Neurology       Date:  2015-05-15       Impact factor: 9.910

4.  Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?-Authors' reply.

Authors:  Carles Gaig; Alex Iranzo; Joan Santamarí; Josep Dalmau; Francesc Graus
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

5.  Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies.

Authors:  Norbert Brüggemann; Klaus-Peter Wandinger; Carles Gaig; Andreas Sprenger; Klaus Junghanns; Christoph Helmchen; Alexander Münchau
Journal:  Mov Disord       Date:  2016-03-31       Impact factor: 10.338

6.  Clinical manifestations of the anti-IgLON5 disease.

Authors:  Carles Gaig; Francesc Graus; Yarko Compta; Birgit Högl; Luis Bataller; Norbert Brüggemann; Caroline Giordana; Anna Heidbreder; Katya Kotschet; Jan Lewerenz; Stefan Macher; Maria J Martí; Teresa Montojo; Jesus Pérez-Pérez; Inmaculada Puertas; Caspar Seitz; Mateus Simabukuro; Nieves Téllez; Klaus-Peter Wandinger; Alex Iranzo; Guadalupe Ercilla; Lidia Sabater; Joan Santamaría; Josep Dalmau
Journal:  Neurology       Date:  2017-04-05       Impact factor: 9.910

7.  The clinical spectrum of Caspr2 antibody-associated disease.

Authors:  Agnes van Sonderen; Helena Ariño; Mar Petit-Pedrol; Frank Leypoldt; Peter Körtvélyessy; Klaus-Peter Wandinger; Eric Lancaster; Paul W Wirtz; Marco W J Schreurs; Peter A E Sillevis Smitt; Francesc Graus; Josep Dalmau; Maarten J Titulaer
Journal:  Neurology       Date:  2016-07-01       Impact factor: 9.910

8.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

9.  Isolated dysphagia as initial sign of anti-IgLON5 syndrome.

Authors:  Jens Burchard Schröder; Nico Melzer; Tobias Ruck; Anna Heidbreder; Ilka Kleffner; Ralf Dittrich; Paul Muhle; Tobias Warnecke; Rainer Dziewas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-11-22

10.  Sleep disorder, chorea, and dementia associated with IgLON5 antibodies.

Authors:  Mateus M Simabukuro; Lidia Sabater; Tarso Adoni; Rubens Gisbert Cury; Mônica Santoro Haddad; Camila Hobi Moreira; Luana Oliveira; Mateus Boaventura; Rosana Cardoso Alves; Leticia Azevedo Soster; Ricardo Nitrini; Carles Gaig; Joan Santamaria; Josep Dalmau; Francesc Graus
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-07-23
View more
  8 in total

1.  Epileptic Seizures and Right-Sided Hippocampal Swelling as Presenting Symptoms of Anti-IgLON5 Disease: A Case Report and Systematic Review of the Literature.

Authors:  Yaoqi Fu; Xiangting Zou; Ling Liu
Journal:  Front Neurol       Date:  2022-05-10       Impact factor: 4.086

Review 2.  Sleep Disturbances Associated with Neurological Autoimmunity.

Authors:  Michelle F Devine; Erik K St Louis
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

3.  Figural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis.

Authors:  Niels Hansen; Sina Hirschel; Winfried Stöcker; Anja Manig; Hannah Sönne Falk; Marielle Ernst; Ruth Vukovich; Inga Zerr; Jens Wiltfang; Claudia Bartels
Journal:  Front Psychiatry       Date:  2020-07-03       Impact factor: 4.157

4.  Autoimmune encephalitis with anti-IgLON5 and anti-GABAB-receptor antibodies: A case report.

Authors:  Ha-Yeun Chung; Jonathan Wickel; Annika Voss; Mihai Ceanga; Josefine Sell; Otto W Witte; Christian Geis
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Anti-IgLON5 Disease: A Case With 11-Year Clinical Course and Review of the Literature.

Authors:  Mette Scheller Nissen; Morten Blaabjerg
Journal:  Front Neurol       Date:  2019-10-02       Impact factor: 4.003

6.  HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease.

Authors:  Carles Gaig; Guadalupe Ercilla; Xavier Daura; Mario Ezquerra; Ruben Fernández-Santiago; Eduard Palou; Lidia Sabater; Romana Höftberger; Anna Heidbreder; Birgit Högl; Alex Iranzo; Joan Santamaria; Josep Dalmau; Francesc Graus
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-08-12

7.  Rare Case of Late-Onset Narcolepsy Type 1.

Authors:  Petra Kovalská; Simona Dostálová; Hana Machová; Petra Nytrová; Eszter Maurovich Horvat; Karel Šonka
Journal:  Case Rep Neurol       Date:  2020-11-12

Review 8.  Anti-IgLON5 Disease - The Current State of Knowledge and Further Perspectives.

Authors:  Natalia Madetko; Weronika Marzec; Agata Kowalska; Dominika Przewodowska; Piotr Alster; Dariusz Koziorowski
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.